Morphogen treatments were added at early and intermediate time points (days 0–3, 10–13 and 14–17) using CHIR99021 (CHIR, WNT pathway activator), XAV939 (WNT pathway inhibitor), rh‑SHH/CS24II (SHH), purmorphamine, FGF‑8B (FGF8), RA, rh‑BMP‑4 (BMP4) and rh‑BMP‑7 (BMP7).
